PTPI — Petros Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $0.99m
- -$6.33m
- $5.11m
- 46
- 75
- 12
- 40
Annual cashflow statement for Petros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.6 | -8.99 | -20 | -8.16 | -14.3 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.56 | -8.16 | 4.62 | -3.5 | 4.25 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.6 | -1.69 | -3.09 | 0.625 | 4.53 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.3 | -11.9 | -12.8 | -7.63 | -2.6 |
| Capital Expenditures | -0.005 | 0 | — | — | -0.025 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.005 | 0 | — | — | -0.025 |
| Financing Cash Flow Items | 21.5 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 30.3 | 18.6 | -1.62 | 11.5 | -7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 15 | 6.71 | -14.4 | 3.91 | -9.63 |